CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, July 28, 2021

In accordance with article 227 of the recast Spanish Securities Market Act (*texto refundido de la Ley del Mercado de Valores*), approved by Royal Legislative Decree 4/2015, of 23 October, and related provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

Pharma Mar, S.A. announces that the Committee for Orphan Medicinal Products (COMP), from the EMA, has given its positive opinion for the approval of Orphan Drug status to Zepzelca® (lurbinectedin) for the treatment of Mesothelioma. The Company plans to commence a Phase III trial with lurbinectedin and lurbinectedin in combination with immunotherapy in the second-line treatment of this type of tumor in 2021.

Please find attached press release that Pharma Mar, S.A. will distribute to the media.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com

PharmaMar receives positive opinion from EMA (COMP) for Orphan Drug Designation of lurbinectedin for Mesothelioma

Madrid, July 28th, 2021. – PharmaMar (PHM:MSE) announces that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has given its positive opinion for Orphan Drug Designation to Zepzelca® (lurbinectedin) for the treatment of Mesothelioma.

PharmaMar plans to commence a Phase III trial with lurbinectedin and lurbinectedin in combination with immunotherapy in the second-line treatment of this type of tumor in 2021.

Lurbinectedin is already marketed in the United States for the treatment of metastatic Small-Cell Lung Cancer and has Orphan Drug Designation for this indication in Europe, the United States, Switzerland and Australia.

Malignant Mesothelioma is a tumor that arises from the mesothelial cells of the pleural, peritoneal or pericardial lining, and is often associated with exposure to asbestos, usually with a very poor prognosis at the time of diagnosis, with pleural mesothelioma the most frequent location. There is currently no cure for most malignant mesotheliomas. Therefore, the goal of current cancer treatments (surgery, radiation therapy and chemotherapy) is to reduce or eliminate symptoms, as well as to prolong Progression-Free Survival (PFS) and/or Overall Survival (OS). It is estimated that the incidence of this type of cancer may increase in the coming years, after the exposure to asbestos as there is a long latency period before a Malignant Mesothelioma forms.

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases

with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.
PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin and PM14. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar also wholly owns other companies: GENOMICA, a molecular diagnostics company; and Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About lurbinectedin

Lurbinectedin (Zepzelca®), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt *Ecteinacidia turbinata* in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464

Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– Capital Markets & Investor Relations Director
María Marín de la Plaza – Capital Markets & Investor Relations
investorrelations@pharmamar.com
Phone: +34 914444500

Or please visit our website at www.pharmamar.com